Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)-Reference-Cited by-同舟云学术

Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Published:2018-02-28 Issue:6 Volume:20 Page:1427-1434
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Davis Timothy M. E.¹^ORCID,Mulder Hillary²,Lokhnygina Yuliya²,Aschner Pablo³,Chuang Lee-Ming⁴,Raffo Grado Carlos A.⁵,Standl Eberhard⁶,Peterson Eric D.²,Holman Rury R.⁷^ORCID,

Affiliation:

1. Medical School; University of Western Australia, Fremantle Hospital; Fremantle Western Australia Australia

2. Duke Clinical Research Institute; Duke University School of Medicine; Durham North Carolina

3. School of Medicine, Pontificia Universidad Javeriana; Hospital Universitario San Ignacio; Bogotá Colombia

4. Department of Internal Medicine; National Taiwan University Hospital; Taipei Taiwan

5. Universidad Andrés Bello; Viña del Mar Chile

6. Munich Diabetes Research Institute; Munich Germany

7. Diabetes Trials Unit; University of Oxford; Oxford UK

Funder

Merck Sharp and Dohme

Merck & Co., Inc., Kenilworth, New Jersey

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13242/fullpdf

Reference38 articles.

1. The role of gut hormones in glucose homeostasis;Drucker;J Clin Invest,2007

2. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016

3. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism;Ahren;Diabetologia,2016

4. Determinants of glycemic response to add-on therapy with a dipeptidyl peptidase-4 inhibitor: a retrospective cohort study using a United Kingdom primary care database;Mamza;Diabetes Technol Ther,2016

5. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease;U.K. Prospective Diabetes Study Group;Diabetes,1995

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability;Diabetes, Obesity and Metabolism;2024-05-27

2. Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations;Diabetes, Metabolic Syndrome and Obesity;2023-11

3. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-07

4. Updates of precision medicine in type 2 diabetes;Cambridge Prisms: Precision Medicine;2023

5. Effect of Glucose Levels on Cardiovascular Risk;Cells;2022-09-28